Throwing light on various aspects of Shivom as a DNA data-hub, a potential global health game-changer, and major new cryptocurrency project, the article presents a holistic view of Shivom’s capability and its prospects in the ICO market and as a driver of healthcare as it strategically integrates blockchain technology with DNA Data.
The article is a must-read for anyone who wants to be further informed about Shivom, the panel of experts on board, insights about the OmiX token, partnerships, use of blockchain and its position among the noteworthy blockchain projects.
An excerpt from the article states, “Shivom ecosystem will function in a decentralized way by using blockchain technologies, integrating the best protocols for advanced encryption and the combination of this with Artificial Intelligence.”
CollinStar Capital, the leaders in fintech and digital currency, pools a large investment into the Shivom project.
CollinStar is one of the biggest Australian-based asset management firms, and are experts in blockchain technology and infrastructure, as well as a proficient cryptocurrency investor. Shivom is very excited to welcome CollinStar’s expertise and contribution to our work building the largest genomic and healthcare data hub around the globe. We are confident that CollinStar’s contribution will help propel our vision forward, and with their backing, we are on our way to changing the healthcare landscape.
Shivom is thrilled to have gained the confidence of blockchain and cryptocurrency experts and we look forward to many more of these announcements in the coming days.
These milestones help motivate us to make Shivom the largest project of its kind, and with backers such as CollinStar, we are confident we can make this happen!
We are extremely grateful for all the support and encouragement we have received from our community thus far and are committed to keep the momentum going.
Shivom is creating a lot of buzz with its unique and futuristic interlocking of blockchain technology and genomic data. Recently, Shivom’s CEO Axel Schumacher and CIO Henry Ines have been featured on the Finance News Network, David Pakman Show, and ICO Review.
The videos offer insights on the project, Shivom’s ICO offering, and include interviews with Co-Founders of Shivom and their vision, respectively.
These videos highlight Shivom’s prospects and its purpose of decentralizing DNA and genomic data while ensuring full control and privacy to the DNA donors and genomic data providers.
Watch the Co-founding team talk to experts and explain the idea behind Shivom’s creation as they also provide a perspective on the future of precision medicine, DNA-based medical research, blockchain solutions and the importance of encrypting sensitive information DNA. In these videos, they also address concerns surrounding Shivom’s proposed use of the blockchain technology and genomic information.
We would also like to inform you that we are nearing the crowd sale event of our OmiX token which is only a few days from now.
One of the most popular YouTube channels on cryptocurrency and blockchain technology, Australia’s #1 Nugget’s News names Shivom as one of the biggest projects to lookout for in the near future.
Nugget’s News team recently reviewed Shivom’s model of building the world’s largest DNA datahub around the globe, and its aim of empowering users and DNA donors with full control and power over the information they share.
Nugget’s viewers are introduced to Shivom’s comprehensive offering, including securing DNA and genomic data storage, monetizing and incentivizing DNA data sharing and encrypting DNA information to prevent violations of privacy. Furthermore, the review describes how Shivom will guide the field of precision medicine, carrying out genetic data collection through global studies in developing countries, and transform the future of healthcare globally.
We are extremely grateful to the Nugget’s News team for their positive response to our project, and for featuring us on their channel! This is a great encouragement to the Shivom team to continue reaching for the top in our goal to advance and revolutionize genomics and precision medicine!
A very warm greeting to our extended Shivom family!
We are thrilled to announce that the presale of our OmiX (OMX) token will commence on April 16th, continuing until April 22nd, 2018. To take advantage of the presale, you need to join our whitelist by signing up at https://shivom.io/public-sale.html
If you have been following Shivom’s journey for the last couple weeks, you are likely aware of all of our amazing recent developments and the overwhelming response our project has received.
Our goal is to democratize DNA data analysis, positively impact precision medicine and securely store genomic information. Shivom has already gained the support of a number of prominent individuals and organizations in the field, and we’re well on our way to gathering even more momentum!
With the Shivom platform everyone will be able to store their DNA data within a secure and privacy-oriented blockchain-based ecosystem, and monetize data sharing with research institutions and pharma companies, to directly impact global healthcare. The OmiX token is the fuel of Shivom’s platform and will be used to drive all data sharing, incentivizing and rewarding of individual DNA data donors. Additionally, it is the required method of exchange by pharma companies, medical institutes, and organizations to collaborate on research studies and access and analyze data.
If you are as excited about our project as we are, and would like to get an early start in joining our ecosystem, then register for the presale event and join our whitelist now!
Genetic testing becomes more common, due to the development of cheaper sequencing technologies, and the growing popularity of inexpensive direct-to-consumer (DTC) genetic testing services. Eventually, most people will undergo genetic testing, not only those with clearly elevated genetic risks. Only recently, Geisinger Health System (GHS), a physician-led health care system in the US, announced that they intend “… to sequence every single patient who comes through the door at Geisinger.” There are good reasons for this approach, genetic testing has some significant benefits, exemplified by a recent paper published by Buchanan and coworkers in the journal Genetics in Medicine1. Their study describes the impact of identifying likely pathogenic BRCA1 and BRCA2 genetic variants in patients who previously didn’t have cancer and were at an age to receive risk mitigating strategies. Out of 26 people who underwent a screening procedure over a 1-year follow-up period, three patients were indeed diagnosed with an early-stage BRCA1/2-associated cancer, demonstrating that screening for pathogenic gene variants among unselected individuals can lead to early disease detection with the potential to intervene at a disease-state when it is still possible.
But what about situations where we cannot intervene with medications or lifestyle changes? For certain diseases we do not yet have a cure, nor can we prevent it; one example is Huntington disease (HD). The disease is a hereditary condition which severely affects the brain and nervous system. The symptoms usually do not occur until people are in their forties or older. The disease is inherited in an autosomal dominant pattern, meaning an affected person has a 50:50 chance to pass the mutation that causes HD to the children. It is this type of information that some healthy, high-risk individuals prefer not to know. Usually, individuals who have a family history and are considering predictive testing should meet with a genetic counselor. Testing for HD is technically easy, but the implications and emotional aftermath of the results are usually anything but straightforward.
However, genetic testing gets more complex with the appearance of whole genome sequencing (WGS); the future of genetic testing. In WGS, all the approx. 3.3 billion base pairs in the genome are sequenced and can potentially provide insight about disease risk. Here, sophisticated algorithms are needed that can filter out those results that we don’t want to know. By providing educational material plus smart contracts on the blockchain (that define those filters), we can make the decision process much easier. To give an example, a person with a family history of breast cancer and HD could specify to be informed about any cancer risk, while no feedback, not positive nor negative, is given in regard to HD. With the rise of WGS testing, any DCT genetic test service provider should empower individuals with easy to understand information to help them evaluate genetic testing options. That is the reason that we at Shivom aim at developing solutions that help people become better informed and to support independent decision-making around these very emotional and personal testing decisions. To help doctors, researchers, and anyone else who deals with genetic testing navigate that minefield, Shivom aims to provide evidence-based information combined with smart contracts. Smart contracts are self-executing contracts with the terms of the agreement between parties being directly written into lines of computer code. The code and the agreements contained therein exist across a distributed, decentralized blockchain network. Using smart contracts, people can decide if they want to learn about their risk of developing certain diseases or not.
. With the rising interests in common and complex diseases genetic testing, it is certain that there will be an exploding need for genetic counselors in complex diseases in the coming few years2. This is one reason why we also aim to build a large global genetic counselor network. Genetic counselors will be responsible to provide education and risk interpretation for consumers as well as supporting health promotion models. Today, there is only one certified genetic counselor for every 80,000 Americans; the situation is even worse in other parts of the world where the profession of genetic counselor is almost unknown.
A global network of genomic/health counselors.
As genomic data become more common in the clinic, it is imperative that clinical scientists and physicians use automated and standardized tools which employ up-to-date methods and curated literature content. Optimizing and standardizing the analysis and interpretation of genomic data means reducing the opportunity for human error and ensuring that interpretation is robust and reproducible by basing it on a foundation of trustworthy scientific content.
1. Buchanan, A. H. et al. Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants. Genet. Med. gim2017145 (2017). doi:10.1038/gim.2017.145
2. Wang, M. H. & Weng, H. Genetic Test, Risk Prediction, and Counseling. Transl. Informatics Smart Healthc.1005, 21–46 (2017).
3. Shelton, C. A. & Whitcomb, D. C. Evolving Roles for Physicians and Genetic Counselors in Managing Complex Genetic Disorders. Clin. Transl. Gastroenterol.6, e124 (2015).
We’re thrilled to announce the launch of the Project Shivom.
Over the last few years genomics and blockchain have reached the potential to significantly improve global healthcare. Genomic medicine has huge implications for the understanding and treatment of as many as 7,000 rare diseases, as well as cancers, complex disease such as cardiovascular and neurodegenerative, and infections. Project Shivom is the next evolutionary step in this development by creating a medical genomics ecosystem on the blockchain. For the first time ever, an ecosystem will offer an open web-marketplace for other providers to add not only genomics information, but also analytics, and associated apps and services to drive personalised medicine. We further aim to extend our services to form a global network of associated laboratories and research centres, as well as genetic counselors and other relevant services. On top of this global ecosystem we will build a not-for-profit R&D organization to serve the underserved, and deliver genomics sequencing technology and targeted health care. Leveraging blockchain technology, the research institute will be based on collaboration and open-innovation, that optimally connects patients, clinicians, researchers, insurers and clinical laboratories to one another. The Shivom platform works on principles of collaboration, openness, and integrity allowing patients to own their genomic data, have full access to it, and monetize it on the blockchain.
Blockchain technology is ideally suited to address most trust issues, such as patient consent, unclear data ownership, data integrity, or user authentication, enabling complex data rights management and fine-grained access using smart contracts. Using state-of-the-art blockchain technology means access to improved data security, easier data sharing, increased patient engagement, better quality ‘big data’ analytics, enhanced R&D processes, and artificial intelligence-based diagnostics for all participants. Our vision is for Shivom to be the largest genomic data-hub on the planet. In doing so, this new massive ecosystem will create value for individuals, not-for-profit organizations, governments, and for-profit entities.
We strongly believe that Shivom will change the fields of genomics, health care, and personalized medicine, for those in remote communities, and for the global system. We urge feedback on our project and whitepaper, and are excited to share further development news with you as it becomes available.